Marjorie G. Zauderer, MD, discusses a currently enrolling Phase 1 clinical trial for mesothelioma patients. This CAR-T cell therapy trial targets mesothelin, a protein heavily expressed in mesothelioma. Moreover, Dr. Zauderer explains what CAR-T cells are, how the CAR-T therapy works, potential side effects, and response expectations.
Dr. Zauderer is an oncologist and co-director of the mesothelioma program at Memorial Sloan Kettering Cancer Center. In addition, she serves as chair of the Foundation’s Board of Directors.
Consequently, the Patient Travel Grant Program covers travel expenses — up to $6,000 — incurred by a patient enrolled in a clinical trial found on clinicaltrials.gov. Additionally, the Foundation covers travel expenses of one caregiver. For more information, please contact Jordan Fingerhut at [email protected].
About CAR-T Cells
Described as “living drugs,” CAR-T cells use a patient’s immune system against a tumor. Put simply, this therapy consists of attacking tumor cells with a patient’s own genetically engineered T cells. In this particular case, a patient’s T cells focus on mesothelin. As a result, they attack the mesothelioma tumor when re-introduced into the patient.
Watch MesoTV
MesoTV and all of its informational videos are possible with the generous support of our donors and sponsors. Importantly, during this difficult time we are able to continue serving, informing, and educating the mesothelioma community. Please take note of our Season 2 sponsors at the beginning of the video: Merck; The Gori Law Firm; Early, Lucarelli, Sweeney & Meisenkothen; and AstraZeneca.
Don’t miss any of our new videos – sign up to receive our news or subscribe to our YouTube Channel by pressing the red “Subscribe” button.
MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.
